ARTICLE | Finance
Shooting F-stars
How BMS deal validates F-star's asset-centric spinout strategy
November 3, 2014 8:00 AM UTC
F-star Alpha Ltd.'s deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller financial flexibility.
F-star Biotechnology Ltd., a subsidiary of F-star GmbH, launched F-star Alpha in October 2013 to develop oncology programs against 23 targets with €9.3 million ($12.9 million) from Atlas Venture, Aescap Venture, TVM Capital, SR One, MP Healthcare Venture Management and MS Ventures (see BioCentury, Oct. 28, 2013)...